Trade Compugen Ltd. - Ordinary Shares - CGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0396 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.1352 |
| Open | 2.1652 |
| 1-Year Change | 12.93% |
| Day's Range | 2.1652 - 2.3252 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 2.2252 | 0.0600 | 2.77% | 2.1652 | 2.3252 | 2.1652 |
| Jan 16, 2025 | 2.1352 | 0.1400 | 7.02% | 1.9952 | 2.2652 | 1.9952 |
| Jan 15, 2025 | 1.9852 | 0.0000 | 0.00% | 1.9852 | 2.0352 | 1.8952 |
| Jan 14, 2025 | 1.9752 | 0.0200 | 1.02% | 1.9552 | 2.1552 | 1.9452 |
| Jan 13, 2025 | 1.9952 | 0.3700 | 22.77% | 1.6252 | 2.0452 | 1.6252 |
| Jan 10, 2025 | 1.6252 | 0.0800 | 5.18% | 1.5452 | 1.6952 | 1.5452 |
| Jan 8, 2025 | 1.5752 | 0.0300 | 1.94% | 1.5452 | 1.6152 | 1.5152 |
| Jan 7, 2025 | 1.5652 | 0.0100 | 0.64% | 1.5552 | 1.6052 | 1.5552 |
| Jan 6, 2025 | 1.5852 | -0.0400 | -2.46% | 1.6252 | 1.6452 | 1.5752 |
| Jan 3, 2025 | 1.5852 | -0.0500 | -3.06% | 1.6352 | 1.6552 | 1.5752 |
| Jan 2, 2025 | 1.6352 | 0.0600 | 3.81% | 1.5752 | 1.6852 | 1.5552 |
| Dec 31, 2024 | 1.5152 | 0.0100 | 0.66% | 1.5052 | 1.5452 | 1.4652 |
| Dec 30, 2024 | 1.4852 | -0.0600 | -3.88% | 1.5452 | 1.5852 | 1.4652 |
| Dec 27, 2024 | 1.5652 | -0.0400 | -2.49% | 1.6052 | 1.6052 | 1.5252 |
| Dec 26, 2024 | 1.6252 | 0.0500 | 3.17% | 1.5752 | 1.6352 | 1.5552 |
| Dec 24, 2024 | 1.5852 | 0.0900 | 6.02% | 1.4952 | 1.6152 | 1.4952 |
| Dec 23, 2024 | 1.4952 | 0.0400 | 2.75% | 1.4552 | 1.5252 | 1.4552 |
| Dec 20, 2024 | 1.5252 | 0.0400 | 2.69% | 1.4852 | 1.5352 | 1.4852 |
| Dec 19, 2024 | 1.5052 | 0.0400 | 2.73% | 1.4652 | 1.5752 | 1.4352 |
| Dec 18, 2024 | 1.4852 | -0.0800 | -5.11% | 1.5652 | 1.5952 | 1.4552 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Compugen Ltd. Company profile
About Compugen Ltd. (USA)
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Compugen Ltd. (USA) revenues increased from $2M to $6M. Net loss increased 15% to $34.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 24% to $26.7M (expense), Interest Income decrease of 49% to $894K (income).
Equity composition
Ordinary Shares NIS.01 Par, 12/10 50M auth., 33,915,545 issd. Insiders own 11.33%. IPO: 8/11/00, 5M shares @ $10 by FleetBoston Robertson Stephens. FY'00 financials are reclassified.
| Industry: | Biotechnology & Medical Research (NEC) |
26 הרוקמים
HOLON
5885849
IL
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com